LBA
BCAX

Letko, Brosseau & Associates’s Bicara Therapeutics BCAX Stock Holding History

Letko, Brosseau & Associates’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Hold
11,175
– – ﹤0.01% 89
2025
Q4 		$188K Buy
+11,175
New +$191K ﹤0.01% 92

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Letko, Brosseau & Associates's BCAX Position: Q1 2026 in Review

Letko, Brosseau & Associates held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 11,175 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #89.

Letko, Brosseau & Associates first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Letko, Brosseau & Associates held 11,175 shares of Bicara Therapeutics worth $222K as of Q1 2026.
  • Letko, Brosseau & Associates left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #89 holding.
  • Letko, Brosseau & Associates first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.